AZD 2066

Drug Profile

AZD 2066

Alternative Names: AZD2066

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Analgesics; Antidepressants; Antiulcers
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Depressive disorders; Gastro-oesophageal reflux; Neuropathic pain

Most Recent Events

  • 31 Dec 2011 Discontinued - Phase-I for Neuropathic pain in Japan (PO)
  • 31 Dec 2011 Discontinued - Phase-I for Neuropathic pain in Sweden (PO)
  • 31 Dec 2011 Discontinued - Phase-I for Neuropathic pain in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top